Compare DAKT & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAKT | INBX |
|---|---|---|
| Founded | 1968 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 944.7M | 999.7M |
| IPO Year | 1996 | 2024 |
| Metric | DAKT | INBX |
|---|---|---|
| Price | $20.15 | $102.31 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $150.00 |
| AVG Volume (30 Days) | 244.2K | ★ 489.3K |
| Earning Date | 03-04-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.75 | N/A |
| Revenue | ★ $608,932,000.00 | $1,300,000.00 |
| Revenue This Year | $12.06 | N/A |
| Revenue Next Year | $9.16 | N/A |
| P/E Ratio | $26.33 | ★ N/A |
| Revenue Growth | 6.89 | ★ 550.00 |
| 52 Week Low | $13.05 | $12.80 |
| 52 Week High | $28.27 | $155.29 |
| Indicator | DAKT | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 54.01 | 45.50 |
| Support Level | $18.99 | $99.20 |
| Resistance Level | $20.55 | $153.14 |
| Average True Range (ATR) | 0.56 | 13.75 |
| MACD | 0.04 | -3.93 |
| Stochastic Oscillator | 64.53 | 8.06 |
Daktronics Inc designs and manufactures electronic scoreboards, programmable display systems, and large-screen video displays for sporting, commercial, and transportation applications. It is engaged in a full range of activities: marketing and sales, engineering and product design and development, manufacturing, technical contracting, professional services, and customer service and support. The company offers a complete line of products, from small scoreboards and electronic displays to large multimillion-dollar video display systems as well as related control, timing, and sound systems. The company has five reportable segments: Commercial, Live Events, High School Park and Recreation, Transportation, and International. The company makes the majority of its revenue from Live events.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.